Novo Nordisk AS Class B NOVO B

Morningstar Rating
Add To Portfolio
Market Closed
kr432.00
24.85 | 5.44%
DKK | Nasdaq OMX Copenhagen | Last close prices updated as of Apr 04, 2025, 5:34 PM CET
  • Last Close
    432
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • Investment Style
    Large Growth
  • Market Cap
    1.9177 Tril
  • Forward Div Yield
    1.28%
  • Trailing Div Yield
    1.28%
  • Price/Sales
    12.51
  • Price/Book
    27.92
  • Beta (5-Year)
    1.17
  • Consensus Forward P/E
    28.01
  • Trailing 12-mo Rev
    290.40

Morningstar's Analysis

Valuation Feb 05, 2025
Currency in DKK
Is it the right time to buy or sell?
Fair ValueLearn Moreplay
1-Star Price
Premium
Economic Moat
Premium
5-Star Price
Premium
Capital Allocation
Premium
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
Author Photo
Karen Andersen, CFA
Director
Business Strategy and Outlook | by Karen Andersen, CFA Updated Feb 05, 2025

As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 34% of the $80 billion-plus diabetes treatment market and roughly half of the more than $15 billion insulin market. Diabetes' prevalence is expected to soar in coming decades as a result of an increasingly overweight and aging population, and we expect Novo to

Morningstar Fair Value Estimate
The Morningstar Fair Value Estimate guides investors to the long-term, intrinsic value of a stock, helping them see beyond the present market price.

Show me how fair value is derived (00:41)

Morningstar calculates the fair value estimate of a company based on a projection of how much cash the company will generate in the future. Morningstar analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. The analyst discounts future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights.

The Morningstar Fair Value Estimate is a projection/opinion and not a statement of fact. If Morningstar's base-case assumptions are true the market price will converge on Morningstar's fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in the future and is no indication of future performance.

Morningstar Equity Research Methodology

Price vs. Fair Value

 
Price/Fair Value
Total Return %
Index Total Return %
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 YTD
55.55 -33.96 34.31 -8.59 32.53 12.57 74.46 29.14 50.36 -9.17 -29.53
38.87 -9.82 19.82 -9.53 29.47 31.27 26.97 0.21 25.87 -4.78 -16.27

Related

Morningstar Research
© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy       Disclosures        Accessibility